ArticleDermatologic therapy2022
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Article in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis.JAMA dermatology · 2024Pooled it
- Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data.British journal of clinical pharmacology · 2026Article
- Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.Life (Basel, Switzerland) · 2026Review
- Efficacy of Risankizumab in Moderate to Severe Psoriasis Considering Body Mass Index: A Scoping Review.Cureus · 2026Review
- IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?Journal of inflammation research · 2026Review
- Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice.Dermatology and therapy · 2025Article
- Therapeutic Advancements in Psoriasis and Psoriatic Arthritis.Journal of clinical medicine · 2025Review
- Real-life Experience of Bimekizumab in 27 Obese Patients with Plaque-type Psoriasis: A 24-week Multicenter Retrospective Study.Dermatology practical & conceptual · 2025Article
- Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review.Journal of clinical medicine · 2025Review
- Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: aFrontiers in pharmacology · 2025Article
- Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).Acta dermato-venereologica · 2024Observational
- The Effects of Smoking, Alcohol, and Dietary Habits on the Progression and Management of Spondyloarthritis.Journal of personalized medicine · 2024Review
- Efficacy and safety of risankizumab in Turkish adults with chronic plaque psoriasis: a one year single-center, retrospective, real-life study.Archives of dermatological research · 2024Article
- A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).Dermatology and therapy · 2024Article
- Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series.JAAD international · 2024Article
- Psoriasis with Leg Involvement as the New Difficult-To-Treat Area: A Cohort Study of Patients Treated With Risankizumab.Dermatology practical & conceptual · 2024Article
- Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review.Annals of dermatology · 2024Article
- Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.American journal of clinical dermatology · 2024Article
- Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE.Drugs in context · 2024Article
- The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.Advances in therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risankizumab has been recently approved for moderate-to-severe plaque psoriasis; however, real-life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response. We retrospectively analyzed 166 patients from two centers in Italy who undergone Risankizumab for psoriasis. The proportion of patients achieving a 100%, 90%, 75% of improvement in Psoriasis Area Severity Index (PASI) and PASI <3 were collected at weeks 16, 28, 40, and 52. Study population was analyzed in subgroups to investigate possible predictors of response to Risankizumab since week 40. At the time of analysis 165, 103, 30, and 11 patients had completed 16, 28, 40, and 52 weeks of treatment, respectively. The mean PASI score decreased from 12.5 ± 5.1 at baseline to 1.9 ± 2.4 at week 16. Similar reductions were observed when considering PASI <3, PASI 75, PASI 90, and PASI 100. Previous biologics failure, different smoking habits, obesity, and joint involvement resulted in a lower response to risankizumab. In particular, significant differences in mean PASI at any time-points was observed between psoriatic arthritis (PSA) and non-PSA patients: 2.7 versus 1.7 (p = 0.036), 1.9 versus 0.4 (p = 0.006), and 4.1 versus 0.5 (p = 0.016) at 16, 28, and 40 weeks, respectively. No difference in response to risankizumab occurred in the case of involvement of difficult-to-treat areas. In this population, Risankizumab was effective and safe. Smoking habits, joint involvement, obese status, and previous biologic experience may negatively affect treatment response, while difficult body sites involvement have minor impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.